Please assess the completion status of the following clinical trial:

Trial Title: Cultured Red Blood Cells : Life Span in Vivo Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Aptitude for donation of PSC validated according to the selection criteria for intra-familial donors of hematopoietic stem cells (HSC):~   * Age \> 18 years and \< 65 years;~  * Search by interview for risk factors pertaining to transmissible diseases;~  * Absence of significant medical antecedents;~  * Absence of severe evolutive pathology (renal, hepatic or cardiac insufficiency);~  * Serological status of the following antibodies (Ab) and antigens (Ag) determined during the 30 days preceding the donation of PSC:~     * anti-HIV 1+2 Ab (2 techniques)~    * P24 antigenemia~    * anti-HCV Ab~    * HBs Ag~    * anti-HBc Ab~    * anti-HBs Ab~    * anti-HTLV I+II Ab~    * syphilis~    * anti-CMV Ab~    * anti-toxoplasmosis Ab~    * anti-EBV Ab Determination of the blood group and search for irregular agglutinins (SIA).~2. Presence in addition of the following clinical and biological characteristics required for an assay in a healthy volunteer:~   * Results of the following biological tests within normal limits or clinically acceptable:~     * hemogram,~    * hepatic functions,~    * renal functions;~    * Absence of hemoglobinopathy on the hemoglobin electrophoresis profile;~    * Absence of G6PD or PK deficiency;~    * Absence of a radiological examination in the context of a research protocol within the last 12 months;~    * Normal arterial pressure controlled after 5 min rest in a reclining position: \< 140 / 90 in three measurements at 2 min intervals;~    * ECG 12 derivations with no particularity;~    * Signature of a specific statement of informed consent to participate in the study of the life span of cRBC, in addition to the donation of HSC.~Exclusion Criteria:~* Women of child-bearing age;~* Donors carrying markers of infection: anti-HIV 1+2 Ab (2 techniques), P24 antigenemia, anti-HCV Ab, HBs Ag, anti-HTLV I+II Ab, syphilis;~* Hemoglobinopathy;~* G6PD or PK deficiency;~* Acute or chronic systemic diseases;~* Antecedents of hypersensitivity to a drug;~* Signs, symptoms or results of biological tests lying outside the limits clinically acceptable for healthy subjects;~* Known allergy to chromium.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): The choice of conducting the study in healthy volunteers and not in patients is based on the necessity to have a healthy physiological context avoiding any situation which could lead to hemolysis. As the protocol requires mobilization with a growth factor, the donors of peripheral stem cells (PSC) receive G-CSF.~Direct intravenous injection of labeled cRBC in a volume of 1 mL will be administered to the subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete